Intravitreal and Subconjunctival Melphalan for Retinoblastoma in Transgenic Mice
Figure 2
Mean tumor burden (40x) following serial subconjunctival injections of 10 mcg/2x a week for 3 weeks and following 1-time administration of 100 μg of melphalan. Both treatment groups demonstrated statistically significant decline in tumor burden.
